噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病的临床疗效

Clinical effect of tiotropium bromide combined with salmeterol fluticazone for chronic obstructive pulmonary disease

目的探讨噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病(COPD)的临床疗效.方法选取金堂县第三人民医院2017年5月-2018年4月收治的COPD患者128例,按照随机数字表法分为对照组与研究组,各64例.对照组患者予以沙美特罗替卡松粉吸入剂治疗,研究组患者在对照组基础上予以噻托溴铵粉吸入剂治疗,两组患者均治疗12周.比较两组患者临床疗效、治疗前后第1秒用力呼气容积(FEV1)、呼吸困难指数(MRC)、六分钟步行距离(6MWT),并观察两组患者不良反应发生情况.结果研究组患者治疗有效率高于对照组(P<0.05).治疗前研究组患者FEV1、MRC和6 MWT比较,差异无统计学意义(P>0.05);治疗后研究组患者FEV1高于对照组,MRC低于对照组,6 MWT长于对照组(P<0.05).两组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论噻托溴铵联合沙美特罗替卡松治疗COPD的治临床效确切,可有效改善患者肺功能,且安全性较高.

Objective To investigate the clinical effect of tiotropium bromide combined with salmeterol fluticazone for chronic obstructive pulmonary disease(COPD).Methods A total of 128 cases of patients with COPD were selected from May 2017 to April 2018 in the Third People's Hospital of Jintang,which were divided into control group and study group according to the method of random digital table,64 cases in each group.The patients control group was treated with salmeterol fluticazone powder inhalation,the study group was treated with thiobromine powder inhalation based on the control group,both groups were treated for 12 weeks.Clinical effect,FEV1,MRC,6 MWT before and after treatment were compared between the two groups, and the incidence of adverse reactions were observed.Results The effective rate of treatment in the study group was higher than control group(P<0.05).There was no significant difference between FEV1,MRC or 6 MWT in the study group before treatment (P>0.05).After treatment,the study group of FEV1 was higher than control group,MRC was lower than control group,and 6 MWT was longer than control group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Tiotropium bromide combined with salmeterol fluticazone have an exact clinical effect for COPD,it can effectively improve the lung function of patients,and with high safety.